

March 29, 2016

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Ref: Your email dated March 29, 2016, enclosing therewith, letter bearing Ref. No. NSE/CM/Surveillance/6204 dated March 29, 2016, requesting confirmation/information on news item appearing in "CNBC TV18".

In response to your above mentioned email, we wish to state as under: -

"There is speculation about a US FDA audit at our Mandideep facilities. We had an audit at our Mandideep location from 2nd Feb, 2016 to 19th Feb, 2016. There were total 3 observations. As the site has both dosage form facility and API facility, 2 separate form 483s were issued with 2 observations each. 1 of the observations was repeated in both the forms as it is relevant to both operations.

We believe that these observations are minor in nature and have already addressed these observations. We believe that the outcome of the audit will be Voluntary Action Indicated only and there will be no remediation required.

One of the observation which was erroneously quoted relates to use of non-conforming intermediate for making API prior to 2015. This was done based on laboratory trials and scientific rationale that further processing steps were capable of producing desired quality API. All API batches and drug product batches manufactured using such APIs complied with the specifications and hence were released to market. Appropriate corrective and preventative actions were already implemented in 2015 and were verified by the FDA investigator. As an abundant precaution, we have since recalled batches manufactured from this period. There is no material financial impact of the recall.

We don't expect any disruption to product supply from our Mandideep location. There are no pending applications from the facility."

Thanking you,

Yours faithfully,
For LUPIN LIMITED


R.V. SATAM

COMPANY SECRETARY

